Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv100–iv118.
Authors: S. Roselló, I. Blasco, L. García Fabregat, A. Cervantes and K. Jordan
Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. Although infusion reactions can be allergic or non-immune-mediated, the clinical manifestations are the same and require prompt assessment and appropriate intervention. These new ESMO Clinical Practice Guidelines provide tools to evaluate the risk of infusion reactions, to recognise the early signs and symptoms and include recommendations on how to document and manage them.